Global ovarian cancer health disparities

Ganna Chornokur, Ernest K Amankwah, Joellen M Schildkraut, Catherine M Phelan, Ganna Chornokur, Ernest K Amankwah, Joellen M Schildkraut, Catherine M Phelan

Abstract

Objective: The objective of this article is to broadly review the scientific literature and summarize the most up-to-date findings on ovarian cancer health disparities worldwide and in the United States (U.S.).

Methods: The present literature on disparities in ovarian cancer was reviewed. Original research and relevant review articles were included.

Results: Ovarian cancer health disparities exist worldwide and in the U.S. Ovarian cancer disproportionately affect African American women at all stages of the disease, from presentation through treatment, and ultimately increased mortality and decreased survival, compared to non-Hispanic White women. Increased mortality is likely to be explained by unequal access to care and non-standard treatment regimens frequently administered to African American women, but may also be attributed to genetic susceptibility, acquired co-morbid conditions and increased frequency of modifiable risk factors, albeit to substantially lesser extent. Unequal access to care is, in turn, largely a consequence of lower socioeconomic status and lack of private health insurance coverage among the African American population.

Conclusions: Our findings suggest the need for policy changes aimed at facilitating equal access to quality medical care. At the same time, further research is necessary to fully resolve racial disparities in ovarian cancer.

Conflict of interest statement

Conflict of interest: All authors declare that they have no conflict of interest.

Copyright © 2012 Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Incidence of ovarian cancer by world region. GLOBOCAN 2008 data. Complete list of countries included in the world regions, is shown in Appendix A. NZ: New Zealand; S.E. Asia: South-Eastern Asia; S.C. Asia: South-Central Asia.
Fig. 2
Fig. 2
A. Ovarian cancer incidence (open symbols) and mortality (closed symbols) rates worldwide (stars) and in the U.S. (circles). B. Mortality/incidence (M/I) ratios. Average worldwide rates were calculated using the GLOBOCAN 2008 database [18]: NHW (Non-Hispanic White) women — Northern, Central, Eastern and Western Europe;H (Hispanic) women — Central and South Americas and Mexico; A (African) women — North and Middle Africa; An (Asian) women — South-East, South-Central and East Asia.

References

    1. Ahmedin J, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
    1. Kosary C. Cancer of the ovary. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, et al., editors. SEER survival monograph: cancer survival among adults: US SEER program, 1988–2001, patient and tumor characteristics. Bethesda (Maryland): National Cancer Institute, SEER Program; 2007.
    1. Parham G, Phillips JL, Hicks ML, Andrews N, Jones WB, Shingleton HM, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer. 1997;80(4):816–26.
    1. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002;84:399–403.
    1. Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS. Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. J Surg Oncol. 2008;97:103–7.
    1. Williams VL, Stockwell HG, Hoffman MS, Barnholtz-Sloan JS. Racial differences in treatment modalities among female residents of Florida diagnosed with epithelial ovarian cancer. J Gynecol Surg. 2010;26(1):15–22.
    1. Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol. 2003;21(8):1530–5.
    1. Morris CR, Sands MT, Smith LH. Ovarian cancer: predictors of early-stage diagnosis. Cancer Causes Control. 2010;21:1203–11.
    1. Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM. Ovarian cancer risk factors in African-American and white women. Am J Epidemiol. 2009;170(5):598–606.
    1. Barnholtz-Sloan JS, Tainsky MA, Abrams J, Severson RK, Qureshi F, Jacques SM, et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer. 2002;94(6):1886–93.
    1. Merrill RM, Anderson AE, Merrill JG. Racial/ethnic differences in the use of surgery for ovarian cancer in the United States. Adv Med Sci. 2010;55(1):93–8.
    1. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660–9.
    1. Wright JD, Doan T, McBride R, Jacobson JS, Hershman DL. Variability in chemo therapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008;98:1197–203.
    1. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol. 2003;21(18):3488–94.
    1. Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control. 2009;20:1139–50.
    1. Kim S, Dolecek TA, Davis FG. Racial differences in stage at diagnosis and survival from epithelial ovarian cancer: a fundamental cause of disease approach. Soc Sci Med. 2010;71:274–81.
    1. Brawley OW. Is race really a negative prognostic factor for cancer? JNCI. 2009;101(14):970–1.
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, GLOBOCAN . Cancer incidence and mortality worldwide: IARC CancerBase No 10 [Internet] Lyon, France: International Agency for Research on Cancer; 2010. Available from: .
    1. Parkin M, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2002;55:74–108.
    1. Kurman RJ, Visvanathan K, Roden R, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008;198(4):351–6.
    1. Clarke-Pearson DL. Screening for ovarian cancer. N Engl J Med. 2009;361:170–7.
    1. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009;6(7):e1000114. .
    1. Sankaranarayanan R. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20(2):207–25.
    1. Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003;90(1):75–82.
    1. Bower JK, Schreiner PJ, Sternfeld B, Lewis CE. Black–White differences in hysterectomy prevalence: the CARDIA study. Am J Public Health. 2009;99(2):300–7.
    1. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA. 1993;270(23):2813–8.
    1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Verma M, editor. Methods in molecular biology, 472 Cancer epidemiology. 2009:413–38. .
    1. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast–ovarian cancer. Cancer. 2009;115(10):2222–33.
    1. Karami S, Young HA, Henson DE. Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev. 2007;31:29–34.
    1. Tetsche MS, Norgaard M, Jacobsen J, Wogelius P, Sorensen HT. Comorbidity and ovarian cancer survival in Denmark, 1995–2005: a population-based cohort study. Int J Gynecol Cancer. 2008;18(3):421–7.
    1. Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14(1):13–22.
    1. Boyce EA, Costaggini I, Vitonis A, Feltmate C, Muto M, Berkowitz R, et al. The epidemiology of ovarian granulosa cell tumors: a case–control study. Gynecol Oncol. 2009;115:221–5.
    1. Morgan MA, Behbakht K, Benjamin I, Berlin M, King SA, Rubin SC. Racial differences in survival from gynecologic cancer. Obstet Gynecol. 1996;88(6):914–8.
    1. Goss E, Lopez AM, Brown CL, Wollins DS, Brawley OW, Raghavan D. American Society of Clinical Oncology policy statement: disparities in cancer care. J Clin Oncol. 2009;27:2881–5.
    1. Berek JS, Bast RC. Ovarian cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RCJ, Gansler TS, Holland JS, Frei E, editors. Cancer medicine 6. London: BC Decker Inc; 2003.
    1. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42:874–9.
    1. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26(6):995–1005.
    1. Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuk A, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009;69:2349.
    1. Peedicayil A, Vierkant RA, Shridhar V, Schildkraut JM, Armasu S, Hartmann LC, et al. Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. Gynecol Oncol. 2009;114(2):260–4.
    1. White KL, Vierkant RA, Phelan CM, Fridley B, Anderson S, Knutson K, et al. Polymorphisms in NF-κB inhibitors and risk of epithelial ovarian cancer. BMC Cancer. 2009;9:170.
    1. Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Phelan CM, Anderson S, et al. Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18(3):935–44.
    1. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res. 2010;16(3):995–1007.
    1. Peedicayil A, Vierkant RA, Hartmann LC, Fridley BL, Fredericksen ZS, White KL, et al. Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One. 2010;5(1):e8884. .
    1. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6.
    1. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.
    1. Harley I, Rosen B, Risch HA, Siminovitch K, Beiner ME, McLaughlin J, et al. Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1. Gynecol Oncol. 2008;109(3):384–7.
    1. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(5):362–79.
    1. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729–36.
    1. Pagán JA, Su D, Li L, Armstrong K, Asch DA. Racial and ethnic disparities in awareness of genetic testing for cancer risk. Am J Prev Med. 2009;37(6):524–30.
    1. Olaya W, Esquivel P, Wong JH, Morgan JW, Freeberg A, Roy-Chowdhury S, et al. Disparities in BRCA testing: when insurance coverage is not a barrier. Am J Surg. 2009;198:562–5.
    1. Schildkraut JM, Murphy SK, Palmieri RT, Iversen ES, Moorman PG, Huang Z, et al. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:473.
    1. Haffty BG, Silber A, Matloff E, Chung J, Lannin D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet. 2006;43:133–7.
    1. Zeimet AG, Reimer D, Concin N, Braun S, Marth C. Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. MEMO. 2008;1:99–102.
    1. Angioli R, Plotti F, Palaia I, Calcagno M, Montera R, Cafà EV, et al. Update on lymphadenectomy in early and advanced ovarian cancer. Curr Opin Obstet Gynecol. 2008;20(1):34–9.
    1. Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2010;20(4):520–8.
    1. Sterling L, van Lonkhuijzen L, Nyangena J, Orango E, Strother M, Busakhala N, et al. Protocol development for ovarian cancer treatment in Kenya: a brief report. Int J Gynecol Cancer. 2011;2(2):424–7.
    1. Chase D, Fedewa S, Chou TS, Chen A, Ward E, Brewster WR. Disparities in the allocation of treatment in advanced ovarian cancer: are there certain patient characteristics associated with nonstandard therapy? Obstet Gynecol. 2012;119(1):68–77.
    1. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120–7.
    1. Goff BA, Matthews BJ, Larson EH, Andrilla HA, Wynn M, Lishner DM, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer. 2007;109:2031–42.
    1. Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007;109:12–9.
    1. Aranda MA, McGory M, Sekeris E, Maggard M, Ko K, Zingmond DS. Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer? Gynecol Oncol. 2008;111:166–72.
    1. Bristow RE, Zahurak ML, Ibeanu OA. Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol. 2011;121(2):364–8.
    1. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118(3):262–7.
    1. Albain KS, Unger JM, Crowley JJ, Coltman CA, Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101:984–92.
    1. Howe HL, Tung KH, Coughlin S, Jean-Baptiste R, Hotes J. Race/ethnic variations in ovarian cancer mortality in the United States, 1992–1997. Cancer. 2003;97(10):2686–93.
    1. Terplan M, Schluterman N, McNamara EJ, Tracy K, Temkin SM. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. Gynecol Oncol. 2010;125(1):19–24.
    1. Winter WE, III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:3621–7.
    1. Temkin SM, Lengyel E, Tergas A, Terplan M. Ovarian cancer treatment in black and white women: a comparison of clinicopathologic factors and outcome. J Clin Oncol. 2008;26(15S):16531.
    1. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal out comes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008;111(2):173–8.
    1. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel. Cancer. 2009;115:4210–7.
    1. Farley JH, Tian C, Rose GS, Brown CL, Risinger JI, Maxwell GL. Ethnicity and clinical outcome for advanced epithelial ovarian cancer patients treated by standard cisplatin/paclitaxel chemotherapy: a combined analysis of gynecologic oncology group clinical trials. J Clin Oncol. 2008;26(15S):5573. ASCO Annual Meeting Proceedings.
    1. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study. Gynecol Oncol. 2003;91:608–15.
    1. Bristow RE, Ueda S, Gerardi MA, Ajiboye OB, Ibeanu OA. Analysis of racial disparities in stage IIIC epithelial ovarian cancer care and outcomes in a tertiary gynecologic oncology referral center. Gynecol Oncol. 2011;122(2):319–23.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅